Cardiovascular Genomics Market (2025-2035)

Cardiovascular diseases continue to represent the single largest contributor to global mortality, creating sustained and growing demand for advanced diagnostic and risk assessment solutions, including genomic testing. According to the World Health Organization, cardiovascular diseases account for approximately 32% of all global deaths, with the prevalence of heart failure exceeding 64 million individuals and atrial fibrillation affecting nearly 60 million people worldwide. The burden of these conditions is expected to grow further, with atrial fibrillation cases projected to potentially double by 2050 as populations age and cardiometabolic risk factors become more widespread.

Inherited cardiovascular disorders represent a critical subset of this burden and are among the most compelling clinical rationales for genomic testing. Hypertrophic cardiomyopathy, the most common inherited cardiac condition, affects approximately 1 in 500 individuals globally. Dilated cardiomyopathy occurs in an estimated 1 in 250–400 individuals, while familial hypercholesterolemia—one of the most prevalent monogenic disorders—affects approximately 1 in 250 but remains significantly underdiagnosed, with fewer than 10% of affected individuals currently identified. Inherited arrhythmia syndromes, including long QT syndrome (approximately 1 in 2,000–2,500 individuals) and Brugada syndrome (approximately 1 in 2,000–5,000), collectively affect hundreds of thousands of people worldwide.

Sudden cardiac death adds a further and particularly urgent dimension to the market. In the United States alone, sudden cardiac death accounts for an estimated 350,000–450,000 deaths annually. Post-mortem genetic testing, or molecular autopsy, has gained increasing guideline support, with diagnostic yields of approximately 25–35% for the identification of causative pathogenic variants. These results support cascade screening of at-risk family members, enabling preventive interventions that can directly reduce future mortality. This dual clinical utility—clarifying cause of death while protecting living relatives—is a powerful driver of genomic testing adoption.

The shift toward precision medicine has become one of the most consequential drivers in the cardiovascular genomics market, as cardiology moves from uniform treatment pathways toward genotype-guided approaches for diagnosis, risk stratification, and therapeutic decision-making. Professional societies including the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society have incorporated genetic testing recommendations into guidelines for multiple inherited cardiovascular conditions, with Class I or Class IIa recommendations now in place for several clinical scenarios spanning cardiomyopathies and inherited arrhythmia syndromes.

The clinical utility of cardiovascular genetic testing is well supported by consistent diagnostic yields across major indications. Pathogenic or likely pathogenic variants are identified in approximately 30–60% of patients with hypertrophic cardiomyopathy, 25–40% of patients with dilated cardiomyopathy, and 40–80% of individuals with well-phenotyped long QT syndrome. These yields translate into tangible clinical outcomes, including confirmation of diagnoses, guidance for implantable cardioverter-defibrillator placement, tailored pharmacotherapy, prognostic assessment, and cascade family screening.

The growth of dedicated cardiogenetics clinics and multidisciplinary care programs has further embedded precision medicine into cardiovascular practice. Academic medical centers and integrated health systems are increasingly building specialized programs that combine cardiology, genetic counseling, molecular genetics, and bioinformatics expertise, serving as hubs for both clinical implementation and translational research. As precision cardiology matures, these programs are expected to expand significantly in both number and scope.